Pailing Biological: The company's strategic plan will long-term draw on the development directions of overseas blood product giants

NightAirdropper · 2026-03-09T19:07:08+00:00

Pailing Biotechnology stated that it will learn from the development strategies of overseas giants and actively expand its biopharmaceutical business, including mergers and acquisitions of related assets. The control rights transaction has been submitted to the relevant authorities for approval and is currently under review. The profit situation for 2025 will be disclosed in subsequent reports.

NightAirdropper

2026-03-09 19:07:08

Abstract generation in progress

Securities Star News, Paladin Biotech (000403) responded to investor questions on the investor relations platform on March 9.

Investor: Is the company considering further mergers and acquisitions of biopharmaceutical assets as part of its strategic layout?

Paladin Biotech Secretary: Dear investor, hello! The company’s strategic vision is to become a leading biotechnology enterprise in the industry. In its medium- and long-term strategic plan, it will draw on the development direction of overseas blood product giants. While deepening and refining blood product development, the company actively explores innovative businesses related to recombination and blood manufacturing, extending along the industry chain upstream and downstream, continuously expanding its biopharmaceutical business layout. For specific details, please refer to the company’s periodic reports regarding future development prospects. Thank you!

Investor: 1. What is the progress of the anti-monopoly review by the State Administration for Market Regulation? Has it been approved? 2. Will the profit in 2025 increase or decrease compared to 2024? 3. Has the approval from the State-owned Assets Supervision and Administration Commission been completed?

Paladin Biotech Secretary: Dear investor, hello! 1. Regarding the control transfer transaction, the transferee has paid 30% of the target shares transfer fee into the joint management account as stipulated in the “Share Transfer Agreement,” and has submitted the approval documents for this transaction to the State-owned Assets Supervision and Administration Commission and the State Administration for Market Regulation. The approval process is currently underway. 2. For the operational performance in 2025, please pay attention to the company’s subsequent disclosure of the 2025 annual report. Thank you!

The above content is compiled from publicly available information by Securities Star and generated by AI algorithm (Network Information Calculation Backup 310104345710301240019). It does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes